News | September 18, 2006

Vulnerable Plaque Study Begins

Enrollment is complete for a landmark study designed to increase clinical understanding of vulnerable plaque, the deadly, lipid-rich coronary plaque that ruptures without warning or symptoms and possibly the source of most heart attacks.

PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) — an Abbott Vascular-sponsored study — will use novel intravascular imaging technology to correlate plaque characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events. The objective is to equip physicians for identifying and treating at-risk patients before a heart attack occurs.

Gregg, Stone, M.D, professor of Medicine at Columbia University Medical Center, is the principal investigator of the PROSPECT study and will present baseline demographic and imaging data from the first group of enrolled patients during the TCT annual scientific sessions in October.

For more information visit www.abbott.com, or www.tct2006.com.


Related Content

News | Cardiovascular Clinical Studies

April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed ...

Home April 20, 2023
Home
News | Cardiovascular Clinical Studies

April 5, 2023 — Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced the release of a new study ...

Home April 05, 2023
Home
News | Cardiovascular Clinical Studies

March 29, 2023 — Irregular sleep patterns may play a role in the pathophysiologic development of cardiovascular disease ...

Home March 29, 2023
Home
News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
Home
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
Home
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
News | Cardiovascular Clinical Studies

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

Home March 06, 2023
Home
Subscribe Now